- SELLAS Life Sciences Group (NASDAQ: SLS) to present preclinical efficacy data of SLS009 at ASCO 2025.
- The presentation will focus on ASXL1 mutated colorectal cancer.
- The full abstract will be available on May 22, 2025, ahead of the presentation on June 2, 2025.
SELLAS Life Sciences Group, Inc. (NASDAQ: SLS), a late-stage clinical biopharmaceutical company, has announced its participation in the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting. The event will be held in Chicago from May 30 to June 3, 2025.
SELLAS will present a poster showcasing the preclinical efficacy data of SLS009 (tambiciclib) in ASXL1 mutated colorectal cancer. The presentation is slated for June 2, 2025, between 1:30 PM and 4:30 PM CDT in Hall A, under abstract #3121. Attendees can view the detailed results on the ASCO website beginning May 22, 2025.
The company's drug candidate, SLS009, is currently undergoing a Phase 2 clinical trial. The study aims to evaluate the drug's safety and efficacy in combination with venetoclax and azacitidine, specifically targeting AML patients with ASXL1 mutations. The trial also seeks to identify potential biomarkers for patient enrichment in future studies.
SELLAS Life Sciences continues to develop novel therapeutics across various cancer types, leveraging its robust pipeline, including the lead product candidate GPS, licensed from Memorial Sloan Kettering Cancer Center.
